These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27773498)

  • 1. Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.
    Lenhard JR; Gall JS; Bulitta JB; Thamlikitkul V; Landersdorfer CB; Forrest A; Nation RL; Li J; Tsuji BT
    Int J Antimicrob Agents; 2016 Dec; 48(6):719-724. PubMed ID: 27773498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.
    Smith NM; Lenhard JR; Boissonneault KR; Landersdorfer CB; Bulitta JB; Holden PN; Forrest A; Nation RL; Li J; Tsuji BT
    Clin Microbiol Infect; 2020 Sep; 26(9):1207-1213. PubMed ID: 32061797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.
    Lenhard JR; Bulitta JB; Connell TD; King-Lyons N; Landersdorfer CB; Cheah SE; Thamlikitkul V; Shin BS; Rao G; Holden PN; Walsh TJ; Forrest A; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2017 Jan; 72(1):153-165. PubMed ID: 27634916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii.
    Rao GG; Ly NS; Diep J; Forrest A; Bulitta JB; Holden PN; Nation RL; Li J; Tsuji BT
    Int J Antimicrob Agents; 2016 Sep; 48(3):331-6. PubMed ID: 27449542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.
    Rao GG; Ly NS; Bulitta JB; Soon RL; San Roman MD; Holden PN; Landersdorfer CB; Nation RL; Li J; Forrest A; Tsuji BT
    J Antimicrob Chemother; 2016 Nov; 71(11):3148-3156. PubMed ID: 27494922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore.
    Lim TP; Tan TY; Lee W; Sasikala S; Tan TT; Hsu LY; Kwa AL
    J Antibiot (Tokyo); 2009 Dec; 62(12):675-9. PubMed ID: 19876075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.
    Hagihara M; Housman ST; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):874-9. PubMed ID: 24277022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.
    Yadav R; Landersdorfer CB; Nation RL; Boyce JD; Bulitta JB
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2286-98. PubMed ID: 25645842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates.
    Singkham-In U; Chatsuwan T
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):169-174. PubMed ID: 29433997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
    Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.
    Marti S; Sánchez-Céspedes J; Alba V; Vila J
    Int J Antimicrob Agents; 2009 Feb; 33(2):181-2. PubMed ID: 18977642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii.
    Douraghi M; Ghalavand Z; Nateghi Rostami M; Zeraati H; Aliramezani A; Rahbar M; Mohammadzadeh M; Ghourchian S; Boroumand MA; Abdollahi A
    J Appl Microbiol; 2016 Aug; 121(2):401-7. PubMed ID: 27171885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
    Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
    Liang R; Wang D; Hu M; Gu Y; Wang M; Hu D; Zhu M; Wang M
    J Antibiot (Tokyo); 2023 Sep; 76(9):540-547. PubMed ID: 37217796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
    Housman ST; Hagihara M; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes.
    Sharma R; Patel S; Abboud C; Diep J; Ly NS; Pogue JM; Kaye KS; Li J; Rao GG
    Int J Antimicrob Agents; 2017 Feb; 49(2):224-232. PubMed ID: 28040408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections.
    Mohd Sazlly Lim S; Naicker S; Ayfan AK; Zowawi H; Roberts JA; Sime FB
    Int J Antimicrob Agents; 2020 Oct; 56(4):106115. PubMed ID: 32721600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.
    Esterly JS; Qi C; Malczynski M; Scheetz MH
    Pharmacotherapy; 2010 Apr; 30(4):354-60. PubMed ID: 20334455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of polymyxin B against carbapenem-resistant Acinetobacter baumannii.
    Thamlikitkul V; Tiengrim S; Seenama C
    J Med Assoc Thai; 2014 Dec; 97(12):1254-8. PubMed ID: 25764631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
    J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.